Academic Background Glioblastoma (GBM) is a highly malignant primary brain tumor. Despite current standard treatments such as surgical resection, radiotherapy, and chemotherapy, the prognosis remains extremely poor, with a median survival of only 14.6 months. Traditional treatments often fail to completely eradicate the tumor and are prone to recur...

Academic Background Glioblastoma (GBM) is one of the most aggressive and heterogeneous central nervous system tumors, with an extremely poor prognosis. Despite the emergence of novel therapies such as anti-angiogenic treatments and immunotherapy in recent years, the survival period of GBM patients remains very limited. GBM cells exhibit unique meta...

Background Introduction Glioblastoma (GBM) is one of the most aggressive brain cancers, with a median survival of approximately 15 months. Despite the use of multimodal treatments including surgery, chemotherapy, and radiotherapy, the overall survival rate of GBM patients has not significantly improved over the past few decades. Recent studies have...

Academic Background Glioblastoma (GBM) is the most common and aggressive primary brain tumor, with significant treatment challenges and a poor prognosis. Despite advancements in surgery, chemotherapy, and radiotherapy, the 5-year survival rate for GBM patients remains below 4%. The recurrence and therapeutic resistance of GBM are primarily attribut...

Study on Connexin43-Mediated Temozolomide Resistance in Glioma through Activation of the E2F1/ERCC1 Axis Academic Background Glioma is the most common and fatal tumor of the central nervous system, with temozolomide (TMZ) being the standard treatment. However, TMZ therapy often leads to tumor recurrence and drug resistance, severely limiting its ef...

Breakthrough Study on KL-50 in Treating Recurrent Glioblastoma Background Glioblastoma (GBM) is a highly malignant brain tumor, particularly in patients with IDH wild-type (IDHwt), who have a very poor prognosis. Although the current standard treatment includes surgical resection, radiotherapy, and Temozolomide (TMZ) chemotherapy, most patients eve...

Academic Background Pituitary adenomas (PAs) are common intracranial tumors with complex pathogenesis, often accompanied by abnormal hormone secretion. Although various treatments, such as dopamine agonists (DAs), are currently available, some patients exhibit drug resistance, leading to suboptimal therapeutic outcomes. Therefore, identifying new t...

Background Introduction Glioma is one of the most common primary tumors of the central nervous system, and its prognosis and treatment methods vary significantly depending on molecular characteristics. In recent years, with the advancement of molecular pathology, IDH (isocitrate dehydrogenase) mutations have been identified as important molecular m...

Reappraisal of Prognostic Factors in CNS WHO Grade 3 Oligodendrogliomas: Insights from the French POLA Cohort Academic Background Oligodendroglioma is a relatively rare primary brain tumor in the central nervous system (CNS), characterized by IDH gene mutations and 1p/19q co-deletion. According to the World Health Organization (WHO) classification ...

Clinical and Genetic Markers of Vascular Toxicity in Glioblastoma Patients: Insights from NRG Oncology RTOG-0825 Academic Background Glioblastoma (GBM) is a highly aggressive form of brain cancer, accounting for nearly 80% of malignant primary brain tumors. Despite standard treatments including surgical resection, radiotherapy, and chemotherapy, th...